Dluh/Vlastní kapitál společnosti Genocea Biosciences Inc
Jaká je hodnota metriky Dluh/Vlastní kapitál společnosti Genocea Biosciences Inc?
Hodnota metriky Dluh/Vlastní kapitál společnosti Genocea Biosciences Inc je N/A
Jaká je definice metriky Dluh/Vlastní kapitál?
Poměr dluhu k vlastnímu kapitálu (debt to equity ratio) udává podíl vlastního kapitálu a cizích zdrojů na financování majetku společnosti.
The debt to equity ratio is generally calculated by dividing debt by equity. The D/E ratio is also known as risk, gearing or leverage. The two components are often taken from the firm's balance sheet or statement of financial position (so-called book value), but the ratio may also be calculated using market values for both, if the company's debt and equity are publicly traded, or using a combination of book value for debt and market value for equity financially. Preferred stock can be considered part of debt or equity. Attributing preferred shares to one or the other is partially a subjective decision but will also take into account the specific features of the preferred shares. When used to calculate a company's financial leverage, the debt usually includes only the long-term debt.
Čemu se věnuje společnost Genocea Biosciences Inc?
Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens, Inhibigens™, that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood.